Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
Enrolling by invitation · NCT07496463 · Registry updated 2026-07-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) | Body Weight, Bone Diseases, Metabolic, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, bone disorder, calcium metabolic disease, hereditary disease, inborn errors of metabolism, inborn metal metabolism disorder, metabolic disease, musculoskeletal system disorder, nutritional disorder, obesity disorder, overnutrition, pseudohypoparathyroidism, pseudohypoparathyroidism type 1A | Enrolling by invitation | Phase 2 | 2026-07-23 | NCT07496463 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Massachusetts General Hospital | 758 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Massachusetts General Hospital | Boston | United States | 1015 |